2021
Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
Wallach JD, Deng Y, McCoy RG, Dhruva SS, Herrin J, Berkowitz A, Polley EC, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Shah ND, Ross JS, Lyon TD. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Network Open 2021, 4: e2130587. PMID: 34677594, PMCID: PMC8536955, DOI: 10.1001/jamanetworkopen.2021.30587.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsSecondary end pointsMyocardial infarctionClinical trialsCardiovascular diseaseProstate cancerCardiovascular eventsEnd pointRisk of MACELarge US administrative claims databasePropensity-matched cohort studyUS administrative claims databasePropensity score-matched patientsAdverse cardiovascular eventsPrimary end pointAdministrative claims databaseProportional hazards regressionRandomized clinical trialsAdministrative claims dataTrial eligibility criteriaMedicare Advantage beneficiariesProstate cancer treatmentReal-world evidenceElectronic health recordsCardiovascular outcomesSecond-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities.
McCoy RG, Van Houten HK, Karaca-Mandic P, Ross JS, Montori VM, Shah ND. Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities. Diabetes Care 2021, 44: 2302-2311. PMID: 34348996, PMCID: PMC8929191, DOI: 10.2337/dc20-2977.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsGLP-1RAsHeart failureRelative risk ratiosDPP-4iMyocardial infarctionOlder patientsCerebrovascular diseaseCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsType 2 diabetes managementDPP-4i therapySecond-line therapyCotransporter 2 inhibitorsPrior myocardial infarctionPeptidase-4 inhibitorsOptumLabs Data WarehouseType 2 diabetesMedicare Advantage beneficiariesMedication classesSGLT2i therapyClinical factorsRisk ratioComparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
McCoy RG, Van Houten HK, Deng Y, Mandic PK, Ross JS, Montori VM, Shah ND. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. JAMA Network Open 2021, 4: e2035792. PMID: 33523188, PMCID: PMC7851726, DOI: 10.1001/jamanetworkopen.2020.35792.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsCommercial insurance beneficiariesMedicare Advantage beneficiariesDPP-4i treatmentGLP-1RAsType 2 diabetesInsurance beneficiariesMedicare AdvantageGlucose levelsGlucagonlike Peptide-1 Receptor AgonistsPeptide-1 receptor agonistsHealth plansCommercial health insurance plansGLP-1RA treatmentRetrospective cohort studyCotransporter 2 inhibitorsInitiation of treatmentPeptidase-4 inhibitorsLow-income patientsSeparate logistic regression modelsAdministrative claims dataCommercial health plansAdjusted annual rateLogistic regression models
2020
Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions
Feder SL, Canavan ME, Wang S, Kent EE, Kapo J, Presley CJ, Ross J, Davidoff AJ. Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions. Journal Of Palliative Medicine 2020, 24: 195-204. PMID: 32673139, PMCID: PMC7840305, DOI: 10.1089/jpm.2020.0193.Peer-Reviewed Original ResearchConceptsCardiopulmonary conditionsOpioid useMedicare Part D prescription claimsPatterns of opioidSevere pain interferenceUse of opioidsInitiation of opioidsMedicare Advantage beneficiariesNon-Hispanic blacksSelf-reported historyNon-Hispanic whitesOpioid prescribingSevere painNoncancer conditionsPain assessmentPain interferencePrescription claimsAdjusted proportionObservational studyPainPatientsOpioidsLogistic regressionOne-yearCancer
2018
Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study
Jeffery MM, Hooten WM, Henk HJ, Bellolio MF, Hess EP, Meara E, Ross JS, Shah ND. Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study. The BMJ 2018, 362: k2833. PMID: 30068513, PMCID: PMC6066997, DOI: 10.1136/bmj.k2833.Peer-Reviewed Original ResearchConceptsMedicare Advantage beneficiariesAverage daily doseDisabled Medicare beneficiariesAged Medicare beneficiariesRetrospective cohort studyDaily doseOpioid useMedicare beneficiariesLong-term useCohort studyCommercial beneficiariesStudy periodUse prevalenceOpioid use prevalenceHigh rateMedicare Advantage populationTerm useAge 65 yearsOpioid use ratesAdministrative claims dataAverage daily dosesProportion of beneficiariesQuarterly prevalenceMorphine equivalentsOpioid prescriptions
2017
Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use
Jeffery MM, Hooten WM, Hess EP, Meara ER, Ross JS, Henk HJ, Borgundvaag B, Shah ND, Bellolio MF. Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use. Annals Of Emergency Medicine 2017, 71: 326-336.e19. PMID: 28967517, PMCID: PMC6295192, DOI: 10.1016/j.annemergmed.2017.08.042.Peer-Reviewed Original ResearchConceptsLong-term opioid useNon-ED settingsOpioid-naive patientsLong-term useOpioid prescriptionsOpioid useCharacteristics of prescriptionsPrescription opioid useLow daily dosesAdministrative claims dataRate of progressionDisabled Medicare beneficiariesMedicare Advantage beneficiariesED prescriptionGuideline concordancePatients 56Patients 58Opioid prescribingCDC guidelinesPrevention guidelinesDaily dosesEmergency departmentCDC recommendationsDays' supplyInclusion criteriaTrends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection
Jeffery MM, Shah ND, Karaca-Mandic P, Ross JS, Rank MA. Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection. The Journal Of Allergy And Clinical Immunology In Practice 2017, 6: 1568-1577.e4. PMID: 28958746, DOI: 10.1016/j.jaip.2017.07.034.Peer-Reviewed Original ResearchConceptsOmalizumab initiationAsthma controlICS-LABAPatient selectionLow adherenceBetter asthma controlCohort of nonusersSuboptimal patient selectionPoor asthma controlLow adherence ratesPatient-level characteristicsLarge US databaseMedicare Advantage beneficiariesAsthma biologicsExacerbation frequencyOmalizumab useIncident useComparison cohortICS/Medication adherenceAdherence ratesPrevalent usersAdministrative claimsAsthmaUtilization trends